Iovance signs $500M at-the-market equity offering with Jefferies, replacing prior facility

IOVANCE BIOTHERAPEUTICS, INC.

New Open Market Sale Agreement with Jefferies allows sale of up to $500M in common stock at the market.
Prior ATM agreement dated February 8, 2021 was terminated concurrent with the new agreement.
Jefferies will receive up to 3.0% commission on gross proceeds from any shares sold.
Sales are discretionary; the company is not obligated to sell any shares.

item 1.01 item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies (effective 2022-11-18).

Action: termination
Agreement: atm program
Counterparty: Jefferies
Effective: 2022-11-18

Exact text from the filing

On November 18, 2022, the Company terminated its Open Market Sale Agreement, dated February 8, 2021, with Jefferies (the “Prior Sales Agreement”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at $500.0 million (effective 2022-11-18).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: $500.0 million
Effective: 2022-11-18

Exact text from the filing

On November 18, 2022, the Company entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“Jefferies”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $500.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “Common Shares”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-120391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.